ClinicalTrials.gg
RecruitingNCT07588386Updated Nov 16, 2026

The Value of Early Postoperative Colonoscopy in The Early Diagnosis of Anastomotic Leakage After Surgery for Low Colorectal Cancer

An interventional study of electronic colonoscopy in Anastomotic Leakage, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Anastomotic Leak with a site in China — 20 open to participants now, 22 under way, 1 of them phase 3. Anastomotic Leak · China.

Planned enrollment
22nd of 30
140 · median 253
Started
2026
with 3 others
No phase
24 of 46
14 open now
Primary completion
2027-06
later than 14 of 21 live
Registered
43rd of 46
by date
Lead sponsor
5 of 46
Nanchong Central Hospital

Among the 46 studies in Anastomotic Leak with a site in China, this one is the 22nd largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 14 of the 21 other live ones, and was the 43rd registered.

Anastomotic Leak

240 studies on the registry are indexed under Anastomotic Leak; 72 are open to participants now.

Browse Anastomotic Leak studies →

Open to participants now

20 of the 46 studies in Anastomotic Leak with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Anastomotic Leak studies recruiting now, 23 (51%) set no upper age limit and 11 (24%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Anastomotic Leak with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether early postoperative colonoscopy is valuable in the early diagnosis of anastomotic leakage after surgery for low colorectal cancer.The main questions it aims to answer are:

  1. Will the median diagnosis time of AL in the intervention group (early colonoscopy group) be significantly shorter than that in the control group?
  2. Can targeted treatment (such as endoscopic vacuum therapy (EVT)) be initiated earlier in the early colonoscopy group, thereby reducing the incidence of AL and the rate of unplanned re-laparotomy?

Researchers will compare the median diagnosis time of AL in the intervention group (early colonoscopy group) with the control group to observe whether early postoperative colonoscopy can detect anastomotic leakage earlier.

Participants will:

Experimental group (early colonoscopy group):

  1. Colonoscopy will be performed on the 5th to 8th day after surgery (the surgeon will decide the specific date within this time window based on the patient's recovery).
  2. Carry out adequate intestinal preparation before the examination (the specific plan is formulated according to the hospital's routine, which may involve antegrade or retrograde enema, etc., and needs to be recorded and standardized).

Control group (routine observation group):

  1. Receive standard postoperative management, including monitoring vital signs, abdominal signs, drainage fluid properties, etc.
  2. Only when clinical symptoms suspected of anastomotic leakage occur (such as persistent fever, worsening abdominal pain, turbid drainage fluid or stool samples), CT scan, gastrointestinal angiography or diagnostic colonoscopy should be performed according to clinical indications.
03

Conditions studied

  • Anastomotic Leakage

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years old.
  2. diagnosed as colorectal adenocarcinoma.
  3. The distance between the lower edge of the tumor and the anal verge is ≤15cm.
  4. Accept laparoscopic or open radical resection and complete primary colorectal or colosal anastomosis.
  5. Voluntarily participate and sign the written .

Exclusion criteria

Exclusion Criteria:

  1. Distant was confirmed by emergency operation, palliative operation or intraoperative metastasis (M1).
  2. Unsatisfactory anastomosis or poor blood circulation were found during the operation, and reinforcement suture or preventive colostomy were performed during the operation.
  3. There are serious for enteroscopy (such as acute myocardial infarction, severe cardiopulmonary insufficiency, blood coagulation dysfunction, etc.).
  4. Pregnant or lactating women.
  5. Previous history of colorectal surgery (except endoscopic polypectomy).
  6. Unable to understand or cooperate with the research process.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Experimental group (early colonoscopy group)

    Behavioral: electronic colonoscopy

  • No intervention
    Control group (routine observation group)

Interventions

  • Behavioralelectronic colonoscopy

    Colonoscopy on days 5 to 8 after colorectal cancer surgery

06

What researchers measure

Primary outcomes

  1. Diagnosis time lag: the number of days from the end of the operation (the last stitch of skin suturing) to the final diagnosis of AL (confirmed by imaging, endoscopic or surgical exploration).

    Time frame: day 30

Secondary outcomes

  1. Diagnostic efficacy: The sensitivity and specificity of early colonoscopy in diagnosing AL, etc.

    Time frame: day 8

  2. Clinical outcomes: AL incidence rate within 30 days (divided into grades A, B, and C).

    Time frame: day 30

  3. Total postoperative days of hospitalization.

    Time frame: 2 months

  4. Safety indicators: the incidence of complications (such as bleeding, perforation, cardiovascular events) directly related to early enteroscopy.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hospital Nanchong Hospital Affiliated to Capital Medical University
    Nanchong, Sichuan 637000, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 59 non-industry interventional studies with no phase under Anastomotic Leak, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 14, 2026
StartActual
Jun 21, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07588386
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jun 21, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Yunhong Tian, Doctor
Contact
drtianyunhong@126.com
86+13508087719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion